Key facts
- Akeylink’s last known valuation is $327.0M (Feb 2023).
- It has raised $60.5M; the latest was Early Stage VC ($28.1M) in Oct 2025.
- Notable investors include Tailong VC, Fujian Huaxing Venture Capital, Ningde State-owned Assets Investment and Operation, People's Capital, Shanghai Huamin Investment — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Akeylink
- ·The full record, as it builds
Funding rounds
No funding rounds for Akeylink are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Akeylink
Provider and developer of oral medicines intended for coronavirus disease. The company offers a 3-chymotrypsin-like protease inhibitor, enabling patients with effective and safe medication for coronavirus disease.
- Sector
- Healthcare
- HQ
- Ningde, China
- Founded
- 2021
- Website
- akeylink.cn/
- Ownership
- Privately Held (backing)
Akeylink doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Akeylink shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Akeylink in its N-PORT filings yet. We sweep new filings monthly.